BVT Call 290 BIIB 20.09.2024/ DE000VM3MVU1 /
2024-05-17 8:55:51 AM | Chg.-0.006 | Bid9:47:33 PM | Ask9:47:33 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.027EUR | -18.18% | 0.025 Bid Size: 250,000 |
0.035 Ask Size: 250,000 |
Biogen Inc | 290.00 USD | 2024-09-20 | Call |
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
04-29
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...